Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that BRAF p.V600E status confers therapeutic sensitivity to Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin in patients with Colorectal Adenocarcinoma.
The European Medicines Agency (EMA) has authorized encorafenib in combination with cetuximab and FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation.
This statement is based on a regulatory approval from the European Medicines Agency:
Encorafenib in combination with cetuximab and FOLFOX is indicated for the first line treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation.